Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Soo Ki Kim
Observed name:
Soo Ki Kim
Institution:
Kobe Asahi Hospital
Observed institutions:
Kyoto University,
Kobe Asahi Hospital
ORCID:
0000-0001-5527-6555
Observed ORCID:
0000-0001-5527-6555
OpenAlex ID:
A5146610954
Serum amyloid A and C ‐reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis
2013
·
Soo Ryang Kim
, Fukuo Kondo
, et al.
·
Hepatology Research
·
12
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
2026
·
Tomomitsu Matono
, Toshifumi Tada
, et al.
·
Journal of Gastroenterology and Hepatology
·
6
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
2026
·
Kaho Aoe
, Toshifumi Tada
, et al.
·
Hepatology
·
1
Primary Hepatic Squamous Cell Carcinoma
2026
·
Soo Ryang Kim
, Soo Ki Kim
, et al.
·
Diagnostics
·
1
A Case of Kikuchi-Fujimoto Disease with Nonspecific Reactive Hepatitis
2026
·
Soo Ryang Kim
, Soo Ki Kim
, et al.
·
Kanzo
PDF
Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma
2026
·
Kazunari Tanaka
, Kunihiko Tsuji
, et al.
·
Hepatology International
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
2026
·
Kazunari Tanaka
, Kunihiko Tsuji
, et al.
·
Hepatology Research
Show more works
View as search
Works count:
7
Citation count:
20
H-index:
2
I10-index:
1
Year
Topic
Type